Abstract:Abstract Introduction: Bone metastases are common among advanced stage breast cancer patients and induce dysregulation of bone remodeling. Crosstalk between cancer cells and the bone niche drives the vicious cycle of bone loss and breast cancer growth. To accelerate discovery of targeted therapies, there is a critical need for experimental models that can mimic breast cancer-induced dysregulation of bone remodeling in patients. Mouse models are the current gold standard, but are low throughput, costly, and cannot fully recapitulate human-human cell interactions. To address these limitations, our goal is to engineer a fully human 3D in vitro model of breast cancer-bone metastasis that can mimic dysregulation of bone remodeling and drug responses in patients, and enable screening of potential new drug candidates. Methods: Two human breast cancer cell lines (MDA-MB-231, MCF-7) were chosen given their well characterized clinical features and tendency to invade bone. Our 3D model comprises an outer ring of tissue engineered (TE) bone and a center of breast cancer cells to mimic invasion through the bone marrow/long bone interface. Human mesenchymal stem cells were encapsulated in 3D gelatin microribbon scaffolds and cultured in osteogenic media for 28 days to form TE bone. Human monocyte-derived osteoclasts were seeded onto the bone, and the center was replaced with GFP-labeled breast cancer cells. Denosumab and zoledronic acid were selected as they are standard treatments for reducing bone loss in patients, and were used to treat the model at 30 μg/mL and 2 μg/mL, respectively. Intermittent parathyroid hormone (iPTH) treatment was selected as it showed efficacy in animal models, and was used to treat the model at 10 μg/mL for 6 hours daily. All groups were treated with drugs for 14 days. Bone volume was assessed using microCT. Cancer cell proliferation and invasion into bone was monitored with fluorescence confocal microscopy. Results: MicroCT imaging showed both breast cancer cell lines induced bone loss in the triculture model, compared to the control with no breast cancer cells in the center. Consistent with known clinical features, the more aggressive cell line (MDA-MB-231) induced a greater amount of bone loss than the less aggressive breast cancer cell line (MCF-7). Consistent with clinical findings, both denosumab and zoledronic acid reduced bone loss in our 3D model, and zoledronic acid further reduced breast cancer cell invasion and proliferation. Finally, the 3D model recapitulated the in vivo drug response of iPTH treatment, reducing bone resorption and breast cancer invasion. Conclusions: Here we report a fully human triculture model of breast cancer-bone metastasis that can mimic key clinical features of breast cancer-induced bone resorption and drug response in patients. Such a 3D model could enable screening of drug candidates with reduced time and cost and enable identification of novel druggable targets. Citation Format: Michelle Tai, Eva C. González Díaz, Callan E. Monette, Joy Wu, Fan Yang. A 3D model of breast cancer-bone metastasis to mimic dysregulation of bone remodeling and drug response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6772.

Bone mineral density affects tumor growth by shaping microenvironmental heterogeneity

Osteoporosis As a Potential Contributor to the Bone Metastases.

Tumor-Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications.

Understanding the Bone in Cancer Metastasis

Collagen Mineralization Decreases Nk Cell‐Mediated Cytotoxicity of Breast Cancer Cells via Increased Glycocalyx Thickness

Abstract 5985: Marrow immune landscape participates dormancy and activation of disseminated tumor cells in a breast cancer bone metastasis model

Collagen mineralization decreases NK cell-mediated cytotoxicity of breast cancer cells via increased glycocalyx thickness

An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche

Bone Endosteal Mimics Regulates Breast Cancer Development and Phenotype

Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment

The bone microenvironment invigorates metastatic seeds for further dissemination

Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts

Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications

Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis

The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells

From breast cancer cell homing to the onset of early bone metastasis: The role of bone (re)modeling in early lesion formation

Bone Metastasis: Find Your Niche and Fit In

Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment

Abstract 6772: A 3D model of breast cancer-bone metastasis to mimic dysregulation of bone remodeling and drug response

Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors

A Multiomic Analysis Reveals How Breast Cancers Disseminated to the Bone Marrow Acquire Aggressive Phenotypes through Tumor-Stroma Tunnels